Heptadecanoic acid inhibits cell proliferation in PC‑9 non‑small‑cell lung cancer cells with acquired gefitinib resistance

  • Authors:
    • Changzhi Xu
    • Pengfei Wu
    • Jiajia Gao
    • Lanlan Zhang
    • Tengfei Ma
    • Bingbing Ma
    • Shuai Yang
    • Guojian Shao
    • Yang Yu
    • Xunduan Huang
    • Xingyuan Yang
    • Buchang Zhang
  • View Affiliations

  • Published online on: April 18, 2019     https://doi.org/10.3892/or.2019.7130
  • Pages: 3499-3507
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Non‑small cell lung carcinomas (NSCLC) are common and are the leading cause of cancer‑associated mortality worldwide. Heptadecanoic acid (C17:0) is an odd‑chain saturated fatty acid. The effect of C17:0 on lung cancer has remained elusive. The present study examined the role of C17:0 in the PC‑9 NSCLC cell line and PC‑9 cells with acquired‑gefitinib resistance (PC‑9/GR) in vitro. Cell proliferation, migration, apoptosis, fatty acid composition and the activation of relevant signaling pathways were assessed. The results indicated that C17:0 significantly inhibited cell proliferation, and migration, while promoting apoptosis in PC‑9 and PC‑9/GR cells. Furthermore, C17:0 enhanced the cytotoxicity of gefitinib to PC‑9 and PC‑9/GR cells. Mechanistical analysis indicated that the activation of the phosphoinositide 3‑kinase/Akt signaling pathway was suppressed in C17:0‑treated PC‑9 and PC‑9/GR cells. Furthermore, the addition of C17:0 led to accumulation of 10‑cis‑heptadecenoic acid in NSCLC cells. Collectively, the present study demonstrated that C17:0 is an effective agent against NSCLC cells in vitro and the results may imply that the intake of C17:1 or C17:0‑rich food may be beneficial during the treatment of NSCLC.
View Figures
View References

Related Articles

Journal Cover

June 2019
Volume 41 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Xu, C., Wu, P., Gao, J., Zhang, L., Ma, T., Ma, B. ... Zhang, B. (2019). Heptadecanoic acid inhibits cell proliferation in PC‑9 non‑small‑cell lung cancer cells with acquired gefitinib resistance. Oncology Reports, 41, 3499-3507. https://doi.org/10.3892/or.2019.7130
MLA
Xu, C., Wu, P., Gao, J., Zhang, L., Ma, T., Ma, B., Yang, S., Shao, G., Yu, Y., Huang, X., Yang, X., Zhang, B."Heptadecanoic acid inhibits cell proliferation in PC‑9 non‑small‑cell lung cancer cells with acquired gefitinib resistance". Oncology Reports 41.6 (2019): 3499-3507.
Chicago
Xu, C., Wu, P., Gao, J., Zhang, L., Ma, T., Ma, B., Yang, S., Shao, G., Yu, Y., Huang, X., Yang, X., Zhang, B."Heptadecanoic acid inhibits cell proliferation in PC‑9 non‑small‑cell lung cancer cells with acquired gefitinib resistance". Oncology Reports 41, no. 6 (2019): 3499-3507. https://doi.org/10.3892/or.2019.7130